QRG Capital Management Inc. Acquires 5,992 Shares of Edwards Lifesciences Corporation (NYSE:EW)

QRG Capital Management Inc. lifted its holdings in Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 7.8% during the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 83,294 shares of the medical research company's stock after purchasing an additional 5,992 shares during the period. QRG Capital Management Inc.'s holdings in Edwards Lifesciences were worth $6,037,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Crowley Wealth Management Inc. bought a new position in shares of Edwards Lifesciences in the 4th quarter worth approximately $26,000. Vega Investment Solutions bought a new position in shares of Edwards Lifesciences in the 4th quarter worth approximately $27,000. Millstone Evans Group LLC bought a new position in shares of Edwards Lifesciences in the 4th quarter worth approximately $29,000. Park Square Financial Group LLC bought a new position in shares of Edwards Lifesciences in the 4th quarter worth approximately $44,000. Finally, Catalyst Capital Advisors LLC bought a new position in shares of Edwards Lifesciences in the 4th quarter worth approximately $54,000. Institutional investors own 79.46% of the company's stock.

Edwards Lifesciences Trading Down 2.0%

EW stock opened at $73.31 on Wednesday. The firm has a fifty day moving average price of $74.77 and a 200 day moving average price of $72.96. Edwards Lifesciences Corporation has a fifty-two week low of $58.93 and a fifty-two week high of $95.25. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.66 and a current ratio of 4.45. The firm has a market cap of $43.00 billion, a PE ratio of 10.47, a price-to-earnings-growth ratio of 3.77 and a beta of 1.12.

Edwards Lifesciences (NYSE:EW - Get Free Report) last posted its earnings results on Wednesday, April 23rd. The medical research company reported $0.64 earnings per share for the quarter, beating analysts' consensus estimates of $0.60 by $0.04. Edwards Lifesciences had a net margin of 75.48% and a return on equity of 16.62%. The firm had revenue of $1.41 billion during the quarter, compared to analyst estimates of $1.40 billion. During the same period last year, the firm posted $0.66 earnings per share. Edwards Lifesciences's revenue for the quarter was up 6.2% compared to the same quarter last year. Sell-side analysts anticipate that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on EW shares. Wall Street Zen cut shares of Edwards Lifesciences from a "buy" rating to a "hold" rating in a research note on Friday, May 16th. Truist Financial decreased their target price on shares of Edwards Lifesciences from $78.00 to $75.00 and set a "hold" rating on the stock in a research note on Friday, April 11th. Piper Sandler raised their target price on shares of Edwards Lifesciences from $80.00 to $83.00 and gave the stock an "overweight" rating in a research note on Tuesday, May 13th. Dbs Bank upgraded shares of Edwards Lifesciences to a "hold" rating in a research note on Monday, June 2nd. Finally, Robert W. Baird raised their target price on shares of Edwards Lifesciences from $72.00 to $75.00 and gave the stock a "neutral" rating in a research note on Thursday, April 24th. One analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and eleven have assigned a buy rating to the company's stock. According to data from MarketBeat, Edwards Lifesciences currently has an average rating of "Hold" and an average price target of $80.20.

Insider Activity at Edwards Lifesciences

In other Edwards Lifesciences news, CFO Scott B. Ullem sold 11,250 shares of Edwards Lifesciences stock in a transaction on Wednesday, March 26th. The shares were sold at an average price of $70.87, for a total transaction of $797,287.50. Following the completion of the transaction, the chief financial officer now directly owns 30,387 shares of the company's stock, valued at $2,153,526.69. The trade was a 27.02% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Donald E. Bobo, Jr. sold 2,570 shares of Edwards Lifesciences stock in a transaction on Monday, June 2nd. The stock was sold at an average price of $77.40, for a total transaction of $198,918.00. Following the transaction, the vice president now directly owns 50,356 shares of the company's stock, valued at $3,897,554.40. The trade was a 4.86% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 51,898 shares of company stock valued at $3,796,154. 0.34% of the stock is owned by corporate insiders.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corporation (NYSE:EW - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.